004720 — PharmGen Science Balance Sheet
0.000.00%
- KR₩74bn
- KR₩75bn
- KR₩171bn
Annual balance sheet for PharmGen Science, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 30,448 | 34,187 | 19,886 | 37,437 | 37,916 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 24,020 | 20,166 | 28,638 | 36,414 | 39,662 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 74,901 | 77,379 | 70,541 | 95,327 | 110,709 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 17,214 | 34,902 | 42,444 | 41,273 | 38,863 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 135,544 | 220,324 | 317,391 | 335,917 | 363,450 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 37,688 | 71,122 | 68,185 | 63,172 | 65,422 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 52,018 | 93,384 | 110,267 | 107,696 | 114,011 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 83,526 | 126,940 | 207,125 | 228,221 | 249,439 |
Total Liabilities & Shareholders' Equity | 135,544 | 220,324 | 317,391 | 335,917 | 363,450 |
Total Common Shares Outstanding |